SCHEMBL6469284

SCHEMBL6469284

CCCC(NC(=O)Cc1cccc(Oc2ccccc2)c1)C(=O)Nc1cnccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.47
THRB P10828 1/20 0.47
FAAH O00519 1/20 0.46
GPR132 Q9UNW8 3/20 0.45
LONP1 P36776 3/20 0.45
S1PR1 P21453 1/20 0.45
PSEN1 P49768 5/20 0.44
PSEN2 P49810 5/20 0.44
APH1B Q8WW43 5/20 0.44
NCSTN Q92542 5/20 0.44
APH1A Q96BI3 5/20 0.44
PSENEN Q9NZ42 5/20 0.44
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
PSMB5 P28074 1/20 0.42
MME P08473 1/20 0.42
ACE P12821 1/20 0.42
CPA1 P15085 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6468928 0.87 FAAH (0.48) GAATHRBFAAHHTTSMN1; SMN2
SCHEMBL6469018 0.87 FAAH (0.47) FAAHGPR132S1PR1PSEN1PSEN2
SCHEMBL6468835 0.86 MME (0.48) GAAGPR132S1PR1PSEN1PSEN2
SCHEMBL5047006 0.85 S1PR1 (0.43) S1PR1PSEN1PSEN2APH1BNCSTN
SCHEMBL5041099 0.84 S1PR1 (0.43) S1PR1PSEN1PSEN2APH1BNCSTN
SCHEMBL3902883 0.79 MME (0.56) GPR132SMN1; SMN2ALDH1A1LMNAPSMB5
SCHEMBL5044820 0.79 PSEN1 (0.63) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8258819 0.79 PSEN1 (0.68) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8258551 0.78 CCNE1 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6466561 0.77 PSEN1 (0.44) GAATHRBLONP1PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA GAA 186/4885THRB 869/4885FAAH 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.